Literature DB >> 7845348

Serogroup B meningococcal disease--Oregon, 1994.

.   

Abstract

In Oregon, the incidence of meningococcal disease has increased substantially, more than doubling from 2.2 cases per 100,000 persons in 1992 to 4.6 per 100,000 in 1994--the highest incidence in Oregon since 1943. This incidence was almost fivefold higher than recent estimates for the United States during 1989-1991 (approximately one case per 100,000 persons annually) (1). This report describes meningococcal disease surveillance data from 1994 and summarizes epidemiologic and laboratory data on serogroup B meningococcal disease in Oregon during 1987-1994.

Entities:  

Mesh:

Year:  1995        PMID: 7845348

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  10 in total

Review 1.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Epidemiology of infant meningococcal disease in the United States, 2006-2012.

Authors:  Jessica R MacNeil; Nancy Bennett; Monica M Farley; Lee H Harrison; Ruth Lynfield; Megin Nichols; Sue Petit; Arthur Reingold; William Schaffner; Ann Thomas; Tracy Pondo; Leonard W Mayer; Thomas A Clark; Amanda C Cohn
Journal:  Pediatrics       Date:  2015-01-12       Impact factor: 7.124

3.  Differences in surface expression of NspA among Neisseria meningitidis group B strains.

Authors:  G R Moe; S Tan; D M Granoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

Authors:  M L Tondella; T Popovic; N E Rosenstein; D B Lake; G M Carlone; L W Mayer; B A Perkins
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Cleavase fragment length polymorphism analysis of Neisseria meningitidis basic metabolic genes.

Authors:  M L Tondella; M W Reeves; T Popovic; N Rosenstein; B P Holloway; L W Mayer
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 6.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

7.  Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis.

Authors:  M W Reeves; B A Perkins; J D Wenger
Journal:  Emerg Infect Dis       Date:  1995 Apr-Jun       Impact factor: 6.883

8.  The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.

Authors:  C M Kahler; L E Martin; G C Shih; M M Rahman; R W Carlson; D S Stephens
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city.

Authors:  Hernando Pinzón-Redondo; Wilfrido Coronell-Rodriguez; Inés Díaz-Martinez; Angel Guzmán-Corena; Dagna Constenla; Nelson Alvis-Guzmán
Journal:  J Health Popul Nutr       Date:  2014-09       Impact factor: 2.000

10.  Epidemiology of meningococcal disease, New York City, 1989-2000.

Authors:  Alexandre Sampaio Moura; Ariel Pablos-Méndez; Marcelle Layton; Don Weiss
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.